Search results for "Life Sciences & Biomedicine"

showing 10 items of 253 documents

MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence

2018

mHealth, such as apps running on consumer smart devices is becoming increasingly popular and has the potential to profoundly affect healthcare and health outcomes. However, it may be disruptive and results achieved are not always reaching the goals. Allergic Rhinitis and its Impact on Asthma (ARIA) has evolved from a guideline using the best evidence-based approach to care pathways suited to real-life using mobile technology in allergic rhinitis (AR) and asthma multimorbidity. Patients largely use over-the-counter medications dispensed in pharmacies. Shared decision making centered around the patient and based on self-management should be the norm. Mobile Airways Sentinel networK (MASK), th…

AllergyHEALTH-ORGANIZATIONIMPACTRespiratory Medicine and Allergy[SDV]Life Sciences [q-bio]Allergic Rhinitis and its Impact on Asthma - ARIAReviewMASK - Mobile Airways Sentinel networK0302 clinical medicine610 Medical sciences MedicineApp; ARIA; Asthma; Care pathways; MASK; mHealth; Rhinitis; Immunology and Allergy; Immunology; Pulmonary and Respiratory MedicineHealth careMedicine and Health SciencesImmunology and Allergy030212 general & internal medicineAndroid (operating system)mHealthRinitisRhinitiComputingMilieux_MISCELLANEOUSLungmedicin och allergiRhinitisPRODUCTIVITY3. Good healthALLERGIC RHINITISmHealthRiniteCare pathwaysMedical emergencyLife Sciences & BiomedicinePulmonary and Respiratory MedicineSTRATEGIESMASKMASK study groupImmunologyMEDLINE610K-ANONYMITYPharmacy[object Object]Settore MED/10 - Malattie Dell'Apparato RespiratorioVALIDATIONMACVIA-ARIA03 medical and health sciencesmedicineMobile technologyTECHNOLOGYApp -MASKApp ; ARIA ; Asthma ; Care pathways ; MASK ; mHealth ; RhinitisARIA; App; Asthma; Care pathways; MASK; Rhinitis; mHealthAsmaAsthmaCare pathwayScience & TechnologyARIAbusiness.industryApp; ARIA; Asthma; Care pathways; MASK; mHealth; RhinitisSettore MED/09 - MEDICINA INTERNACorrectionGuidelineRC581-607medicine.diseaseAsthma030228 respiratory systemImmunologic diseases. AllergybusinessAppEUROPEAN COUNTRIES[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Bacterial Viruses Subcommittee and Archaeal Viruses Subcommittee of the ICTV: Update of taxonomy changes in 2021

2021

In this article, we – the Bacterial Viruses Subcommittee and the Archaeal Viruses Subcommittee of the International Committee on Taxonomy of Viruses (ICTV) – summarise the results of our activities for the period March 2020 – March 2021. We report the division of the former Bacterial and Archaeal Viruses Subcommittee in two separate Subcommittees, welcome new members, a new Subcommittee Chair and Vice Chair, and give an overview of the new taxa that were proposed in 2020, approved by the Executive Committee and ratified by vote in 2021. In particular, a new realm, three orders, 15 families, 31 subfamilies, 734 genera and 1845 species were newly created or redefined (moved/promoted). Supplem…

Archaeal VirusesSocieties ScientificviruksetLibrary scienceBiologybakteriofagitExecutive committee03 medical and health sciencesVirology Division NewsVirologyvirusesBacteriophages030304 developmental biologyTaxonomy11832 Microbiology and virology0303 health sciencesScience & TechnologyBacteria030306 microbiologysystematiikka (biologia)Archaeal VirusesGeneral MedicineArchaeaVirologyvirologia[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/VirologyTaxonomy (biology)Bacterial virusLife Sciences & Biomedicine
researchProduct

Advances in understanding mineral dust and boundary layer processes over the Sahara from Fennec aircraft observations

2015

Abstract. The Fennec climate programme aims to improve understanding of the Saharan climate system through a synergy of observations and modelling. We present a description of the Fennec airborne observations during 2011 and 2012 over the remote Sahara (Mauritania and Mali) and the advances in the understanding of mineral dust and boundary layer processes they have provided. Aircraft instrumentation aboard the UK FAAM BAe146 and French SAFIRE (Service des Avions Français Instrumentés pour la Recherche en Environnement) Falcon 20 is described, with specific focus on instrumentation specially developed for and relevant to Saharan meteorology and dust. Flight locations, aims and associated met…

Atmospheric Science010504 meteorology & atmospheric sciencesMeteorologyPlanetary boundary layerCONVECTIVE SYSTEMEnvironmental Sciences & EcologyAEROSOL OPTICAL-PROPERTIESMineral dust010502 geochemistry & geophysicsAtmospheric sciences01 natural sciencesCOARSE MODElcsh:ChemistryHaboobDust storm0201 Astronomical and Space SciencesMeteorology & Atmospheric SciencesSatellite imagerySOUTHERN MOROCCO0105 earth and related environmental sciences[PHYS.PHYS.PHYS-AO-PH]Physics [physics]/Physics [physics]/Atmospheric and Oceanic Physics [physics.ao-ph]GBScience & TechnologyHEAT LOWAIRBORNE OBSERVATIONSRETRIEVAL PRODUCTSOzone depletionlcsh:QC1-999PARTICLE-SIZEAERONETBoundary layerlcsh:QD1-99913. Climate action[SDU.STU.CL]Sciences of the Universe [physics]/Earth Sciences/ClimatologyPhysical SciencesWEST-AFRICAN MONSOONEnvironmental science0401 Atmospheric SciencesNORTH-ATLANTIC OCEANLife Sciences & Biomedicinelcsh:PhysicsEnvironmental SciencesAtmospheric Chemistry and Physics
researchProduct

Hyperspectral response of agronomic variables to background optical variability: Results of a numerical experiment

2022

Understanding how biophysical and biochemical variables contribute to the spectral characteristics of vegetation canopies is critical for their monitoring. Quantifying these contributions, however, remains difficult due to extraneous factors such as the spectral variability of canopy background materials, including soil/crop-residue moisture, soil-type, and non-photosynthetic vegetation (NPV). This study focused on exploring the spectral response of two important agronomic variables (1) leaf chlorophyll content (Cab ) and (2) leaf area index (LAI) under various canopy backgrounds through a global sensitivity analysis of wheat-like canopy spectra simulated using the physically-based PROSAIL …

Atmospheric ScienceResilient LivelihoodsLEAF-AREA-INDEXSoil typePHOTOCHEMICAL REFLECTANCE INDEXBIOPHYSICAL PROPERTIESMeteorology & Atmospheric SciencesAdaptationLeaf chlorophyll contentGlobal and Planetary ChangeScience & TechnologyVEGETATION INDEXESSPECTRAL INDEXESGLOBAL SENSITIVITY-ANALYSISAgricultureNon-photosynthetic vegetationForestry22/4 OA procedureAgronomyHyperspectral responseGlobal sensitivity analysisITC-ISI-JOURNAL-ARTICLEPhysical SciencesLeaf area indexCHLOROPHYLL CONTENTGREEN LAILife Sciences & BiomedicineCANOPY REFLECTANCEAgronomy and Crop ScienceRADIATIVE-TRANSFER MODELAgricultural and Forest Meteorology
researchProduct

Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoG…

2019

This multicenter/multinational, open-label, ascending-dose study (NCT01898364) evaluated safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of repeat-dose avalglucosidase alfa (neoGAA), a second-generation, recombinant acid α-glucosidase replacement therapy, in late-onset Pompe disease (LOPD). Patients ≥18 years, alglucosidase alfa naïve (Naïve) or previously receiving alglucosidase alfa for ≥9 months (Switch), with baseline FVC ≥50% predicted and independently ambulatory, received every-other-week avalglucosidase alfa 5, 10, or 20 mg/kg over 24 weeks. 9/10 Naïve and 12/14 Switch patients completed the study. Avalglucosidase alfa was well-tolerated; no deaths…

Avalglucosidase alfa (neoGAA)0301 basic medicineMaleGLUCOSE TETRASACCHARIDELysosomal acid alpha-glucosidase (GAA) deficiencyCHILDRENPulmonary function testingMOTOR FUNCTION0302 clinical medicineMedicineGenetics (clinical)Late-onset Pompe disease (LOPD)Glycogen Storage Disease Type IIAlglucosidase alfaMOUSE MODELEnzyme replacement therapyMiddle AgedTreatment OutcomeNeurologyTolerabilityEnzyme replacement therapySKELETAL-MUSCLEFemaleLife Sciences & BiomedicineMUSCLE TRAINING RMTGlycogen6-MINUTE WALKmedicine.drugAdultmedicine.medical_specialtyClinical NeurologyGLYCOGEN03 medical and health sciencesFEV1/FVC ratioPharmacokineticsInternal medicineHumansEnzyme Replacement TherapyAdverse effectAlglucosidase alfaScience & Technologybusiness.industryNeurosciencesalpha-GlucosidasesADULTSGlycogen storage disease type IISEVERITY030104 developmental biologyPharmacodynamicsPediatrics Perinatology and Child HealthNeurosciences & NeurologyNeurology (clinical)Glucan 14-alpha-Glucosidasebusiness030217 neurology & neurosurgeryNeuromuscular Disorders
researchProduct

Deregulation of miR-324/KISS1/kisspeptin in early ectopic pregnancy: mechanistic findings with clinical and diagnostic implications

2019

[Abstract] BACKGROUND: Ectopic pregnancy is a life-threatening condition for which novel screening tools that would enable early accurate diagnosis would improve clinical outcomes. Kisspeptins, encoded by KISS1, play an essential role in human reproduction, at least partially by regulating placental function and possibly embryo implantation. Kisspeptin levels are elevated massively in normal pregnancy and reportedly altered in various gestational pathologic diseases. Yet, the pathophysiologic role of KISS1/kisspeptin in ectopic pregnancy has not been investigated previously. OBJECTIVE: The purpose of this study was to evaluate changes of KISS1/kisspeptin levels in ectopic pregnancy and thei…

BIOMARKERdiagnosisEctopic pregnancyPlacentaUNKNOWN LOCATIONPhysiology0302 clinical medicineKisspeptinPregnancyDiagnosis030212 general & internal medicineKisspeptins030219 obstetrics & reproductive medicineEctopic pregnancyObstetrics & GynecologyObstetrics and GynecologyPregnancy Ectopicmedicine.anatomical_structureectopic pregnancyBiomarker (medicine)GestationFemaleKISSPEPTINLife Sciences & BiomedicineSERUM PROGESTERONEhormones hormone substitutes and hormone antagonistsmiR-324-3pEXPRESSIONDown-RegulationGestational AgeReal-Time Polymerase Chain ReactionVALIDATION03 medical and health sciencesKisspeptinsPlacentamicroRNAmedicineHumansMESSENGER-RNASRNA MessengerObstetrics & Reproductive MedicinePregnancyScience & Technologybusiness.industryDecision TreesKISS 1BiomarkerEmbryo Mammalianmedicine.diseaseMicroRNAsEarly DiagnosisCase-Control Studies1114 Paediatrics and Reproductive MedicineKISS1businessBiomarkers
researchProduct

Development of Polyamine‐Substituted Triphenylamine Ligands with High Affinity and Selectivity for G‐Quadruplex DNA

2019

Currently, significant efforts are devoted to designing small molecules able to bind selectively to guanine quadruplexes (G4s). These noncanonical DNA structures are implicated in various important biological processes and have been identified as potential targets for drug development. Previously, a series of triphenylamine (TPA)-based compounds, including macrocyclic polyamines, that displayed high affinity towards G4 DNA were reported. Following this initial work, herein a series of second-generation compounds, in which the central TPA has been functionalised with flexible and adaptive linear polyamines, are presented with the aim of maximising the selectivity towards G4 DNA. The acid-bas…

Biochemistry & Molecular BiologyCircular dichroismChemistry Medicinal0601 Biochemistry and Cell BiologyLigands010402 general chemistryTriphenylamineG-quadruplex01 natural sciencesBiochemistryFluorescence spectroscopyStructure-Activity Relationshipchemistry.chemical_compoundFluorescence Resonance Energy TransferPolyaminesPharmacology & PharmacyCOORDINATION CHEMISTRYPROBEMolecular BiologyScience & Technology0304 Medicinal and Biomolecular Chemistry010405 organic chemistryOrganic ChemistryDNACombinatorial chemistrySmall molecule0104 chemical sciences* G-quadruplex DNA * G4 selectivity * polyamine-based ligand *fluorescenceG-QuadruplexesFörster resonance energy transferchemistryDrug DesignFRETEQUILIBRIUM-CONSTANTSMolecular MedicineCOMPLEXESfluorescenceEMISSIONSelectivityLife Sciences & BiomedicineDNAChemBioChem
researchProduct

Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1…

2012

OBJECTIVE We evaluated the addition of liraglutide to metformin in type 2 diabetes followed by intensification with basal insulin (detemir) if glycated hemoglobin (A1C) ≥7%. RESEARCH DESIGN AND METHODS In 988 participants from North America and Europe uncontrolled on metformin ± sulfonylurea, sulfonylurea was discontinued and liraglutide 1.8 mg/day added for 12 weeks (run-in). Subsequently, those with A1C ≥7% were randomized 1:1 to 26 weeks’ open-label addition of insulin detemir to metformin + liraglutide (n = 162) or continuation without insulin detemir (n = 161). Patients achieving A1C <7% continued unchanged treatment (observational arm). The primary end point was A1C change bet…

Blood GlucoseMaleEXENATIDEendocrine system diseasesdiabetes liraglutide metfortmin hypoglycemiaEndocrinology Diabetes and Metabolismmedicine.medical_treatmentType 2 diabetesTHERAPYGastroenterologyMELLITUSInsulin DetemirGlucagon-Like Peptide 1GLYCEMIC CONTROLOriginal ResearchInsulin detemirAged 80 and overClinical Care/Education/Nutrition/Psychosocial ResearchTREATED PATIENTSMiddle AgedMetforminMetforminNPH INSULINInsulin Long-ActingFemaleLife Sciences & Biomedicinehormones hormone substitutes and hormone antagonistsmedicine.drugAdultmedicine.medical_specialtyPARALLEL-GROUPAdolescentmedicine.drug_classHypoglycemiaEndocrinology & MetabolismDiabetes mellitusInternal medicineInternal MedicinemedicineHumansHypoglycemic AgentsCOMBINATIONAgedGlycated HemoglobinAdvanced and Specialized NursingScience & TechnologyLiraglutidebusiness.industryInsulin26-WEEKnutritional and metabolic diseasesLiraglutideEFFICACYmedicine.diseaseSulfonylureaEndocrinologyDiabetes Mellitus Type 2business
researchProduct

Routine Use of Budesonide/Formoterol Fixed Dose Combination in Elderly Asthmatic Patients: Practical Considerations

2017

Asthma has been demonstrated to be as common in the elderly as in younger age groups. Although no specific recommendations exist to manage the disease differently in older individuals, functional features and clinical presentations may be affected by age per se, and by age-related conditions, such as comorbidities and polypharmacy. In this review article, we aimed to explore the efficacy and safety in elderly asthmatic patients of one of the most currently used inhaled treatments for asthma, that is, the fixed-dose combination of budesonide/formoterol. We attempted to address some practical questions that are relevant to the daily practice of clinicians. We focused on the efficacy and real-…

BudesonideGeriatrics & GerontologyDatabases Factuallaw.invention0302 clinical medicineRandomized controlled trialRELIEVER THERAPYlawBudesonide Formoterol Fumarate Drug CombinationDrug InteractionsPharmacology (medical)Anti-Asthmatic AgentsPharmacology & Pharmacy030212 general & internal medicineEMPHYSEMATOUS LUNGSGeriatricsPRIMARY-CAREGeriatrics and Gerontology Pharmacology (medical)Middle AgedRANDOMIZED CONTROLLED-TRIALSINGLE INHALERTreatment OutcomeDrug InteractionPractice Guidelines as TopicLife Sciences & BiomedicineHumanmedicine.drugmedicine.medical_specialtySettore MED/10 - Malattie Dell'Apparato RespiratorioOBSTRUCTIVE PULMONARY-DISEASE03 medical and health sciencesAdministration InhalationmedicineAnti-Asthmatic AgentHumansOLDER-PEOPLEIntensive care medicineAgedAsthmaPolypharmacyAIRWAY CLEARANCEScience & Technologybusiness.industryDRY POWDER INHALERSmedicine.diseaseAsthma030228 respiratory systemBudesonide/formoterolLUNG DEPOSITIONGeriatricsPhysical therapyIndacaterol1115 Pharmacology And Pharmaceutical SciencesFormoterolGeriatrics and GerontologybusinessDrugs & Aging
researchProduct

Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel

2015

Statins are one of the most commonly prescribed drugs in clinical practice. They are usually well tolerated and effectively prevent cardiovascular events. Most adverse effects associated with statin therapy are muscle-related. The recent statement of the European Atherosclerosis Society (EAS) has focused on statin-associated muscle symptoms (SAMS), and avoided the use of the term 'statin intolerance'. Although muscle syndromes are the most common adverse effects observed after statin therapy, excluding other side effects might underestimate the number of patients with statin intolerance, which might be observed in 10 - 15% of patients. In clinical practice, statin intolerance limits effecti…

CHRONIC KIDNEY-DISEASERANDOMIZED CONTROLLED-TRIALSMuscle symptomPLACEBO-CONTROLLED TRIALMedicine General & InternalMuscular DiseasesCardiovascular DiseaseGeneral & Internal MedicineDefinition; Muscle symptoms; Risk factors; Statin intolerance; Cardiovascular Diseases; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscular Diseases; Pharmacology (medical); Medicine (all)Humansdefinitionrisk factorsPharmacology (medical)CORONARY-HEART-DISEASETHROMBOTIC THROMBOCYTOPENIC PURPURAcardiovascular diseasesFATTY LIVER-DISEASEDyslipidemiasPRIMARY BILIARY-CIRRHOSISScience & TechnologyMuscular DiseasePOST-HOC ANALYSISMedicine (all)nutritional and metabolic diseases1103 Clinical SciencesCOA-REDUCTASE INHIBITORSDyslipidemiaDENSITY-LIPOPROTEIN CHOLESTEROLCardiovascular Diseasesmuscle symptomslipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorRisk factorPosition PaperHydroxymethylglutaryl-CoA Reductase InhibitorsLife Sciences & BiomedicineHumanstatin intoleranceArchives of Medical Science : AMS
researchProduct